Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Enzymatic Reduction of "Biogenic" Aldehydes in Brain

BORIS TABAKOFF, ROBERT ANDERSON and SPYRIDON G. A. ALIVISATOS
Molecular Pharmacology July 1973, 9 (4) 428-437;
BORIS TABAKOFF
Department of Biochemistry, The Chicago Medical School, Chicago, Illinois 60612
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBERT ANDERSON
Department of Biochemistry, The Chicago Medical School, Chicago, Illinois 60612
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SPYRIDON G. A. ALIVISATOS
Department of Biochemistry, The Chicago Medical School, Chicago, Illinois 60612
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Aldehyde derivatives of the biogenic amines (e.g., serotonin, dopamine) were prepared enzymatically, purified, and used as substrates for aldehyde reductase (EC 1.1.1.2), an enzyme capable of reducing these deaminated derivatives. The enzyme was partially purified from rat brain tissue. Aldehyde reductase derived from brain tissue differed from alcohol dehydrogenase (EC 1.1.1.1) in cofactor specificity and was inhibited by low concentrations of barbiturates (i.e., pentobarbital). The presence of various functional groups on the parent phenylacetaldehyde or indoleacetaldehyde structures was shown to significantly affect the Michaelis constants (Km, Vmax) for aldehyde reductase. The relationship between Michaelis constants determined for aldehyde reductase and the final product of biogenic amine metabolism in rat brain is discussed.

ACKNOWLEDGMENTS The authors wish tO thank Miss MaryLu Prendergast and Mr. Terry Bercovitz for their fine technical assistance.

  • Copyright ©, 1973, by Academic Press, Inc.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 9, Issue 4
1 Jul 1973
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Enzymatic Reduction of "Biogenic" Aldehydes in Brain
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Enzymatic Reduction of "Biogenic" Aldehydes in Brain

BORIS TABAKOFF, ROBERT ANDERSON and SPYRIDON G. A. ALIVISATOS
Molecular Pharmacology July 1, 1973, 9 (4) 428-437;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Enzymatic Reduction of "Biogenic" Aldehydes in Brain

BORIS TABAKOFF, ROBERT ANDERSON and SPYRIDON G. A. ALIVISATOS
Molecular Pharmacology July 1, 1973, 9 (4) 428-437;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antimicrobial and Antileukemic Transportan 10 Conjugates
  • Pharmacological characterization of zebrafish H1 receptor
  • Bhave and Forman
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics